Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -27.27% is 50% above its 5-year average of -55.08%, near the high end of its 5-year range (-117.99%–-27.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 67.13% above its 12-month average of -82.96%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -27.27%.
RETURN ON EQUITY (ROE)
-27.27%
RETURN ON EQUITY (ROE) AVG TTM
-82.96%
RETURN ON EQUITY (ROE) AVG 3Y
-64.82%
RETURN ON EQUITY (ROE) AVG 5Y
-55.08%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+67.13%
CURRENT VS 3Y AVG
+57.93%
CURRENT VS 5Y AVG
+50.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
+32.18%
vs the sector median at left
InflaRx N.V.
Market Cap
$240.09M
Return on Equity (ROE)
-27.27%
TTM Avg
-82.96%
3Y Avg
-64.82%
5Y Avg
-55.08%
Market Cap
$240.66M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$240.31M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$237.25M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
Market Cap
$243.34M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$243.66M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$243.81M
Return on Equity (ROE)
N/A
TTM Avg
-1340.59%
3Y Avg
-55.32%
5Y Avg
-61.68%
Market Cap
$236.14M
Return on Equity (ROE)
-34.04%
TTM Avg
-95.97%
3Y Avg
-70.55%
5Y Avg
-68.40%
Market Cap
$244.64M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InflaRx N.V. (IFRX) | $240.09M | -27.27% | -82.96% | -64.82% | -55.08% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.66M | N/A | -125.28% | -42.20% | -43.41% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.31M | -118.58% | 62.37% | -376.78% | -340.60% |
| High Tide Inc. (HITI)vs › | $237.25M | -31.55% | -30.05% | -33.97% | -37.95% |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | N/A | 35.05% | 64.68% | -167.54% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | -1340.59% | -55.32% | -61.68% |
| MacroGenics, Inc. (MGNX)vs › | $236.14M | -34.04% | -95.97% | -70.55% | -68.40% |
| Invivyd, Inc. (IVVD)vs › | $244.64M | -59.27% | -136.66% | -113.26% | -53.68% |
| BioAge Labs Inc. (BIOA)vs › | $235.40M | -25.20% | -25.82% | 5.12% | 5.12% |
ROE
-27.3%
ROA
-23.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -27.27% |
| 2026-03-31 | -117.99% |
| 2025-12-31 | -108.36% |
| 2025-09-30 | -85.78% |
| 2025-06-30 | -75.41% |
| 2025-03-31 | -63.70% |
| 2024-12-31 | -78.58% |
| 2024-09-30 | -85.66% |
| 2024-06-30 | -57.63% |
| 2024-03-31 | -43.85% |
| 2023-12-31 | -41.01% |
| 2023-09-30 | -30.00% |
| 2023-06-30 | -27.44% |
| 2023-03-31 | -32.72% |
| 2022-12-31 | -33.17% |
| 2022-09-30 | -38.16% |
| 2022-06-30 | -40.52% |
| 2022-03-31 | -58.33% |
| 2021-12-31 | -44.29% |
| 2021-09-30 | -37.10% |
| 2021-06-30 | -29.73% |
| 2021-03-31 | -22.91% |
| 2020-12-31 | -41.22% |
| 2020-09-30 | -41.57% |
| 2020-06-30 | -50.28% |
| 2020-03-31 | -51.40% |
| 2019-12-31 | -49.49% |
| 2019-09-30 | -41.70% |
| 2019-06-30 | -32.28% |
| 2019-03-31 | -20.47% |
| 2018-12-31 | -20.32% |
| 2018-09-30 | -20.38% |
| 2018-06-30 | -18.22% |
| 2018-03-31 | -26.74% |
| 2017-12-31 | -19.69% |
